Last reviewed · How we verify
HIPEC with Mitomycin-C — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
HIPEC with Mitomycin-C (HIPEC with Mitomycin-C) — Memorial Sloan Kettering Cancer Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HIPEC with Mitomycin-C TARGET | HIPEC with Mitomycin-C | Memorial Sloan Kettering Cancer Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HIPEC with Mitomycin-C CI watch — RSS
- HIPEC with Mitomycin-C CI watch — Atom
- HIPEC with Mitomycin-C CI watch — JSON
- HIPEC with Mitomycin-C alone — RSS
Cite this brief
Drug Landscape (2026). HIPEC with Mitomycin-C — Competitive Intelligence Brief. https://druglandscape.com/ci/hipec-with-mitomycin-c. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab